
Jayant Narlikar: Remembering the Indian scientist who challenged the Big Bang theory
In his 1983 science fiction story, an Indian astrophysicist predicted what schools would look like in 2050. Jayant Narlikar envisioned a scene where an alien, living among humans, would sit in front of a screen and attend online classes. The aliens are yet to manifest, but online classes became a reality for students far sooner, in 2020, when the Covid-19 pandemic hit.Narlikar also famously proposed an alternative to the Big Bang Theory - the popular idea that the universe was created in a single moment from a single point. He believed that the universe had always existed, expanding continuously into infinity.With his passing on Tuesday, India lost one of its most celebrated astrophysicists. Narlikar was 86 - a man far ahead of his times and someone who shaped a generation of Indian researchers through his lifelong dedication to science education.His funeral was attended by hundreds, from school children to renowned scientists and even his housekeeping staff, underscoring the profound impact he had on society.
Born on 19 July, 1938, in the town of Kolhapur in the western state of Maharashtra, Narlikar was raised in a home steeped in academic tradition. His father, Vishnu Narlikar, was a professor and mathematician, and mother Sumati was a scholar of the Sanskrit language.Following in his parents footsteps, the studious Narlikar went to Cambridge University for higher studies where topped a highly prestigious mathematical course. He also took a deep interest in astrophysics and cosmology.But his most significant episode at Cambridge was his association with his PhD guide, physicist Sir Fred Hoyle. Together, Narlikar and Hoyle laid the groundwork for a revolutionary alternative to the popular Big Bang theory.The two physicists contested the Big Bang Theory, which posits that all matter and energy in the universe came into existence in one single instance about 13.8 billion years ago.The Hoyle-Narlikar theory boldly proposed the continuous creation of new matter in an infinite universe. Their theory was based on what they called a quasi-steady state model.In his autobiography, My Tale of Four Cities, Narlikar used a banking analogy to explain the theory. "To understand this concept better, think of capital invested in a bank which offers a fixed rate of compound interest. That is, the interest accrued is constantly added to the capital which therefore grows too, along with the interest." He explained that the universe expanded like the capital with compound interest. However, as the name 'steady state' implies, the universe always looks the same to the observer.Astronomer Somak Raychaudhury says that though Narlikar's theory isn't as popular as the Big Bang, it is still useful."He advanced mechanisms by which matter could be continually created and destroyed in an infinite universe," Raychaudhary said. "While the Big Bang model gained broader acceptance, many tools developed for the steady-state model remain useful today," he addedRaychaudhary recollects that even after Hoyle began to entertain elements of the Big Bang theory, Narlikar remained committed to the steady-state theory. A sign outside his office fittingly stated: "The Big Bang is an exploding myth."
Narlikar stayed in the UK till 1971 as a Fellow at King's College and a founding member of the Institute of Theoretical Astronomy. As he shot to global fame in the astrophysics circles, the science community in India took note of his achievements.In 1972, he returned to India and immediately took charge of the Theoretical Astrophysics Group at the coveted Tata Institute of Fundamental Research, which he led it till 1989.But his biggest contribution to India was the creation of an institution dedicated to cutting-edge research and the democratisation of science.This dream materialised in 1988, when Narlikar, along with other distinguished scientists, founded the Inter-University Centre for Astronomy and Astrophysics (IUCAA) in Pune city in western India.From a modest 100sq ft room, IUCAA has gone on to become an internationally respected institution for astronomy and astrophysics. Narlikar served as its founder-director till 2003, and continued to be an emeritus professor after that.He insisted that IUCAA should include programs aimed at school children and the general public. Monthly lectures, science camps, and workshops became regular events.Recalling Narlikar's vision for the institution, science educator Arvind Gupta says, "He said PhD scholars don't fall from the sky, you must catch them young. He offered me a place to stay, told me to try running the children's science centre for six months, and I ended up staying 11 years. He gave me wings to fly."Despite being a prolific scholar who published over 300 research papers, Narlikar never confined himself to being just a scientist. He also authored many science fiction books that have been translated into multiple languages.These stories were often grounded in scientific principles.In a story called Virus, published in 2015, he envisioned a pandemic taking over the world; his 1986 book Waman Parat Na Ala (The Return of Vaman), tackled the ethical dilemmas of artificial intelligence.Sanjeev Dhurandhar, who was part of the Indian team that contributed to the physical detection of gravitational waves in 2015, recalled how Narlikar inspired him to attempt the unthinkable."He gave me a complex problem early in my research. After I struggled for a week, he solved it on the board in 15 minutes - not to show superiority, but to guide and inspire. His openness to gravitational waves was what gave me the courage to pursue it."A well-known rationalist, Narlikar also took it upon himself to challenge pseudoscience. In 2008, he co-authored a paper that challenged astrology using a statistical method.Raychaudhary said that his motivation to challenge pseudoscience came from the belief system of questioning everything that did not have a scientific basis. But when it came to science, Narlikar believed in exploring the slimmest of possibilities.In his last days, Narlikar continued doing what he loved most - replying to children's letters and writing about science on his blog.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
11 hours ago
- Daily Mail
Subtle warning signs of 'silent disease' 16m Americans are living with and don't know
Nearly 16 million people have the most deadly type of liver disease, yet 80 percent of them have no idea. About five percent of adults worldwide have metabolic dysfunction-associated steatohepatitis (MASH) a serious liver condition caused by fat buildup, inflammation, and scarring. It's the most dangerous type of fatty liver disease MASH triggers liver scarring, which can progress to cirrhosis, and significantly increases the risk of heart disease, chronic kidney disease, and liver cancer. Just one in five Americans with the condition are actually diagnosed. Most patients do not experience symptoms until the damage is irreversible, making it a 'silent disease'. However, as the condition progresses, individuals may experience fatigue, pain or discomfort in the upper right belly, unexplained weight loss, weakness, and in some cases, jaundice (yellowing of the skin and eyes). A coalition of researchers from the US, Europe, and South Africa said that MASH-related liver failure and other complications, including deaths, are becoming more severe and common. The scientists behind the report, published in The Lancet Regional Health Europe, are calling for a doubling in MASH diagnosis rates from the 2022 level, about 13 percent (the current rate is just under 20 percent). They estimated that about 2.6 million people in the US, UK, Germany, and France have been diagnosed with MASH. But if testing were adequately improved and scaled up to become more accessible and commonplace, that figure could balloon to 6.1 million. People with type 2 diabetes, obesity, and heart disease should be prioritized for blood work and other screening tests, which will need to skyrocket from about two million to 36 million. Follow-up testing also needs to jump by nearly 1,300 percent to meet patient needs, and in more settings than liver clinics, such as family doctors' offices, and with diabetes and heart doctors. People with diabetes are especially prone to liver damage leading to MASH. Around 30 to 60 percent of diabetics also have MASH. Obesity is another leading risk factor, with estimates suggesting that 75 percent of overweight people and 90 percent with obesity will develop the condition. People with MASH also have a tripled risk of also developing heart disease, including coronary artery disease, stroke, and heart failure, compared to people without the condition. MASH diagnosis is poised for a major shift, mirroring past breakthroughs in chronic disease management. With new treatments approved and others on the horizon, the focus now turns to fixing systemic roadblocks. Currently, limited access to non-invasive tests and reliance on specialists leave most cases undetected until late stages. MASH arises from a cascade of liver damage typically linked to a buildup of fat in the liver, which triggers inflammation that damages liver cells and activates scar-forming cells. What was once healthy liver tissue becomes stiff, progressively crippling the liver's ability to detoxify blood. Though this is often painless until the damage becomes too severe to be reversed. If caught early, people can live normal lifespans with MASH. Lifestyle changes - eating a healthier diet, exercising regularly, and losing between five and 10 percent of one's body weight - can slow down the progression of MASH and repair some of the damage. Doctors may prescribe resmetirom, the first FDA-approved medication for MASH, to work hand-in-hand with those lifestyle changes. But severe damage can cause deadly conditions that cut a person's life drastically short. 'Each late-stage MASH diagnosis represents a missed opportunity for earlier intervention to prevent disease progression, threatening worse [liver] and [non-liver] outcomes for people living with the condition and greater costs for individuals, health systems, and societies,' researchers told a Barcelona medical conference this week. The solution requires concrete changes from moving diagnostics to implementing automated tools in electronic records. The researchers said that success in improving diagnostics goes beyond devising better tests. A fundamental reworking of methods of care is needed that catches at-risk patients before irreversible damage occurs. 'Paradigm shifts do not occur in a vacuum, but arise when leaps in science, technology, and innovation are coupled with changes in perception and understanding within a community,' they said. 'A confluence of factors in 2024 and expected drug approvals in many European countries in 2025 point to a near term tipping point for MASH diagnoses; nonetheless, focused and sustained efforts are needed to turn such opportunities into reality.'


The Independent
16 hours ago
- The Independent
This common prescription drug could reduce deaths by sepsis, study finds
Critically ill patients with sepsis who are given statins may be more likely to survive, new research suggests. Researchers set out to explore whether the cholesterol-busting drugs may bring additional benefits for patients. The new study examined information on sepsis patients who received statins during a stint in intensive care and compared it with patients in a similar situation who did not receive statins. Some 14.3 per cent of 6,000 sepsis patients who were given statins died within 28 days. This is compared with 23.4 per cent of 6,000 patients who did not receive statin therapy. The research team from China said that this equates to a 39 per cent reduced risk of death within a month. The research, based on data from thousands of patients at a hospital in Israel between 2008 and 2019, also found that 7.4 per cent of statin patients died while in the intensive care unit compared with 13.6 per cent of those who did not receive statins. And during their overall hospital stay, some 11.5 per cent of sepsis patients who were given statins died, compared with 19.1 per cent of sepsis patients who did not take statins. However, it appeared that those who were not prescribed statins had a slightly shorter hospital stay compared with those who did receive them – an average of eight days compared with almost 10 days. 'We found that statin users exhibited decreased 28-day all-cause mortality,' the authors wrote in the journal Frontiers in Immunology. Sepsis is a life-threatening reaction to an infection that occurs when the immune system overreacts and starts to damage the body's tissues and organs. In the UK, 245,000 people are affected by sepsis every year. UK sepsis experts said that 'anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored' as they called for larger trials to confirm the findings. Statins are known as cholesterol-busting drugs because they can help lower the level of low-density lipoprotein (LDL) cholesterol in the blood. But experts said that they also have other benefits, including reducing inflammation and antibacterial effects. The research team called for larger trials to confirm their findings. 'Our large, matched cohort study found that treatment with statins was associated with a 39 per cent lower death rate for critically ill patients with sepsis, when measured over 28 days after hospital admission,' said Dr Caifeng Li, the study's corresponding author and an associate professor at Tianjin Medical University General Hospital in China. 'These results strongly suggest that statins may provide a protective effect and improve clinical outcomes for patients with sepsis.' Commenting on the study, Dr Ron Daniels, founder and chief executive of the UK Sepsis Trust, said: 'It has been known for some time that the anti-inflammatory properties of statins confer a survival benefit on those who take them if they develop sepsis. 'Whilst previous studies have failed to show a similar survival benefit in treating people with sepsis with statins, this new study supports calls for a large, multi-country, randomised control trial. 'Anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored.'


BreakingNews.ie
16 hours ago
- BreakingNews.ie
Statins can reduce sepsis deaths, study suggests
People who are critically ill with sepsis may be more likely to survive if they are given statins, a new study suggests. Researchers wanted to explore whether the cholesterol-busting drugs may bring additional benefits for patients. Advertisement The new study examined information on sepsis patients who received statins during a stint in intensive care and compared it with patients in a similar situation who did not receive statins. Some 14.3 per cent of 6,000 sepsis patients who were given statins died within 28 days. This is compared with 23.4 per cent of 6,000 patients who did not receive statin therapy. The research team from China said that this equates to a 39 per cent reduced risk of death within a month. Advertisement The research, based on data from thousands of patients at a hospital in Israel between 2008 and 2019, also found that 7.4 per cent of statin patients died while in the intensive care unit compared with 13.6 per cent of those who did not receive statins. And during their overall hospital stay, some 11.5 per cent of sepsis patients who were given statins died, compared with 19.1 per cent of sepsis patients who did not take statins. However, it appeared that those who were not prescribed statins had a slightly shorter hospital stay compared with those who did receive them – an average of eight days compared with almost 10 days. 'We found that statin users exhibited decreased 28-day all-cause mortality,' the authors wrote in the journal Frontiers in Immunology. Advertisement Sepsis is a life-threatening reaction to an infection that occurs when the immune system overreacts and starts to damage the body's tissues and organs. In Ireland, about 12,000 people are affected by sepsis every year, according to the HSE. Sepsis experts said that 'anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored' as they called for larger trials to confirm the findings. Statins are known as cholesterol-busting drugs because they can help lower the level of low-density lipoprotein (LDL) cholesterol in the blood. Advertisement But experts said that they also have other benefits, including reducing inflammation and antibacterial effects. The research team called for larger trials to confirm their findings. 'Our large, matched cohort study found that treatment with statins was associated with a 39 per cent lower death rate for critically ill patients with sepsis, when measured over 28 days after hospital admission,' said Dr Caifeng Li, the study's corresponding author and an associate professor at Tianjin Medical University General Hospital in China. 'These results strongly suggest that statins may provide a protective effect and improve clinical outcomes for patients with sepsis.' Advertisement Ireland Sepsis: Doctors launch awareness campaign about le... Read More Commenting on the study, Dr Ron Daniels, founder and chief executive of the Sepsis Trust, said: 'It has been known for some time that the anti-inflammatory properties of statins confer a survival benefit on those who take them if they develop sepsis. 'Whilst previous studies have failed to show a similar survival benefit in treating people with sepsis with statins, this new study supports calls for a large, multi-country, randomised control trial. 'Anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored.'